Tharimmune Enhances Board with Vincent LoPriore Appointment

Tharimmune, Inc., a biotechnology company focusing on novel immunology and oncology solutions, announced Vincent LoPriore's appointment to its Board of Directors. This increases the Board size to seven members. LoPriore, founder of Gravitas Capital and co-founder of President Street Global, brings three decades of financial market experience.

This strategic move aligns with Tharimmune's growth phase, product development, and clinical advancements. Chairman Randy Milby highlighted LoPriore's extensive network and investment strategy experience as essential to advancing Tharimmune's immunotherapy pipeline.

LoPriore, who has managed investment funds over $150 million and engaged in investments exceeding $500 million, aims to collaborate with the Board to address unmet medical needs while enhancing shareholder value.